Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers

Figure 5 Schematic of new Bromodomain and extra-terminal molecules targeting Bromodomain-containing protein 4 using PROTACs technology. The bifunctional molecules contain two binders with one (usually bromodomain and extra-terminal inhibitors like JQ-1 or OTX015) targeting Bromodomain-containing protein 4 (BRD4) and the other binding E3 Ligase, which triggers the ubiquitination and degradation of BRD4. BRD4: Bromodomain-containing protein 4.